Lack of correlation between defective cell-mediated-immunity and levels of secreted or circulating cytokines in a study of 90 cancer-patients.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  International Journal of Oncology

• Publication date

  1994-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/IJO.5.6.1211PMID 21559700
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum and ascitic fluid levels of interleukin‐1, interleukin‐6, and tumor necrosis factor‐alpha in patients with ovarian epithelial cancer

  1993cited by this paper
• Cytokines and their role in the pathophysiology of cancer cachexia.

  1992cited by this paper
• Serum levels of helper factors (IL-1 alpha, IL-1 beta and IL-6), T-cell products (sCD4 and sCD8), sIL-2R and beta 2-microglobulin in patients with B-CLL and benign B lymphocytosis.

  1992cited by this paper
• The interleukin-2/interleukin-2 receptor system: structural, immunological, and clinical features

  1992cited by this paper
• Evidence for the involvement of interleukin 6 in experimental cancer cachexia.

  1992cited by this paper
• Interleukin-6 in clinical medicine

  1991cited by this paper
• Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia.

  1991cited by this paper
• Immunomodulatory effect of tumor necrosis factor

  1991cited by this paper
• Increased levels of soluble interleukin-2 receptors in serum of patients with lung cancer.

  1990cited by this paper
• Correlation of Serum Interleukin-2 Levels, Soluble Interleukin-2 Receptors and T Lymphocyte Subsets in Cancer Patients

  1990cited by this paper
• Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation

  1989cited by this paper
• Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus.

  1988cited by this paper
• Biology of interleukin 1

  1988cited by this paper
• Role of interleukin-2 (IL-2) in cancer-related immune deficiency: in vitro response to IL-2, production of IL-2, and IL-2 receptor expression in patients with advanced cancer.

  1988cited by this paper
• A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

  1987cited by this paper
• Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease.

  1987cited by this paper
• Interleukin 2 (IL 2) relationships with the cancer-related immunodeficiency: in vitro response to exogenous IL 2 by PHA-activated and non PHA-activated peripheral blood mononuclear cells from cancer patients.

  1987cited by this paper
• The released interleukin 2 receptor binds interleukin 2 efficiently.

  1986cited by this paper
• Peripheral Blood Lymphocyte Response to Exogenous Interleukin 2 by PHA-Prestimulated and Non-PHA-Prestimulated Cells in Patients with Cancer

  1986cited by this paper
• Depressed in vitro peripheral blood lymphocyte response to mitogens in cancer patients: The role of suppressor cells

  1977cited by this paper

• Sheep cheese naturally enriched in α-linolenic, conjugated linoleic and vaccenic acids improves the lipid profile and reduces anandamide in the plasma of hypercholesterolaemic subjects

  2012cites this paper
• Medroxyprogesterone acetate in the management of cancer cachexia

  2009cites this paper
• Production of Inflammatory Molecules in Peripheral Blood Mononuclear Cells from Severely Glucose-6-Phosphate Dehydrogenase-Deficient Subjects

  2007cites this paper
• Proinflammatory Cytokines: Their Role in Multifactorial Cancer Cachexia

  2006cites this paper
• Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.

  2003cites this paper
• Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.

  2002cites this paper
• Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites

  2001cites this paper
• Escape Mechanisms in Tumour Immunity

  2001cites this paper
• Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites

  2000cites this paper
• Escape mechanisms in tumor immunity: a year 2000 update.

  2000cites this paper
• Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha‐lipoic acid and N‐acetyl cysteine

  2000cites this paper
• High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer.

  1998cites this paper
• Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients.

  1997cites this paper
• Tumor‐associated lympho‐monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines

  1997cites this paper
• Medroxyprogesterone acetate reduces the production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients.

  1997cites this paper
• Clinical and immunological evaluation of schizophyllan (SPG) in combination with standard chemotherapy in patients with head and neck squamous cell carcinoma.

  1997cites this paper
• Cisplatin induces serotonin release from human peripheral blood mononuclear cells of cancer patients and methylprednisolone inhibits this effect.

  1997cites this paper
• Pilot study of cytokine profiles in prostate cancer patients undergoing proton or conventional radiotherapy.

  1996cites this paper